DGAP-News: Andera Partners / Key word(s): Financing Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs 03.05.2022 / 11:05
DGAP-News: Andera Partners / Key word(s): Financing Andera Partners supports Tubulis in a €60 million Series B financing to accelerate the development of its ADCs 03.05.2022 / 11:05 The issuer is solely responsible for the content of this announcement. Press Release Andera Partners supports Tubu.
Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec and Fund+. All existing investors
ExeVir, a Ghent, Belgium-based company developing single domain antibody therapies providing broad protection against viral infections, closed its Series A financing raising a total of US$50m.
The financing, announced in March 2021, was led by Fund+ with participation from VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices. In conjunction with the funding, Caroline Thielen, Investment Manager at SRIW will join the Board of ExeVir Bio alongside Torsten Mummenbrauer, CEO of ExeVir Bio, Philippe Monteyne, Partner at Fund+, Erica Whittaker, Head of UCB Ventures, Jérôme Van Biervliet, Managing Director at VIB, Stef Heylen representing SFPI-FPIM, Professor Michel Kazatchkine as independent director and Katja Rosenkranz, Partner at V-Bio Ventures (observer), Joel Henneghien at Vives IUF (observer) and Louis Declerck at Fund+ (observer).